search
Back to results

Brief Motivational Enhancement Therapy for Concurrent Disorders

Primary Purpose

Psychosis, Substance Use

Status
Terminated
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Brief Motivational Enhancement Therapy
treatment as usual
Sponsored by
Centre for Addiction and Mental Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Psychosis focused on measuring Psychosis, Substance Use, Motivational Enhancement Therapy

Eligibility Criteria

16 Years - 65 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Between the ages of 16-65
  • DSM-IV Diagnoses of a psychotic disorder and a substance use disorder (tobacco, alcohol and/or drug)
  • Fluent English speaker
  • Capable of giving written informed consent

Exclusion Criteria:

  • Any medical or neuropsychiatric condition, illness or disorder (e.g. unstable angina, severe dementia) that could compromise attendance to outpatient appointments.
  • Inability to provide informed consent.

Sites / Locations

  • Centre for Addiction and Mental Health

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Brief Motivational Enhancement Therapy

treatment as usual

Arm Description

Outcomes

Primary Outcome Measures

CD group attendance
The primary outcome engagement with outpatient CD service as measured by CD group attendance.

Secondary Outcome Measures

Alcohol Use Scale (AUS)/Drug Use Scale (DUS)
The secondary outcome is change in substance use as measured by the AUS and DUS

Full Information

First Posted
August 7, 2013
Last Updated
December 16, 2014
Sponsor
Centre for Addiction and Mental Health
search

1. Study Identification

Unique Protocol Identification Number
NCT01924039
Brief Title
Brief Motivational Enhancement Therapy for Concurrent Disorders
Official Title
Brief Motivational Enhancement Therapy for Individuals With Psychotic Disorders and Concurrent Substance Use Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
December 2014
Overall Recruitment Status
Terminated
Why Stopped
Not enough study participants
Study Start Date
June 2013 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre for Addiction and Mental Health

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The investigators are proposing a project that will examine the effectiveness of brief motivational enhancement therapy in a population with concurrent psychotic disorders and substance use disorders. This study will represent an emerging line of inquiry, as best practice interventions with this concurrent disordered (CD) populations are yet to be established.
Detailed Description
Motivational enhancement therapy (MET) is grounded in research that explores the process of change. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change. The Two MET sessions adapted from Sampl and Kadden (2001) are prepared as two individual sessions to reflect the original design of MET, allowing for client's to be met at their respective stage of change. Further, individual sessions allow the treatment to be tailored to client's individual reasons for change and personal coping strategies. The use of the Personalized Feedback Report (PFR) further encourages treatment around client's personal concerns and goals (Ramchand et al., 2011; See appendix 1 for further detail). In the first treatment session, the therapist provides feedback from the initial CD consultation, using the PFR to stimulate discussion about personal substance use and reasons for change. Rapport building is also a key element to the first session, during which a strong therapeutic alliance is initiated. The second session is aimed at strengthening the commitment to change, exploring goal setting, and preparation for group. The Centre for Addiction and Mental Health (CAMH) Schizophrenia Division introduced a CD service in 2009. Since the time of its inception, more than 200 consultations have been conducted. Of those consultations, more than 80%recommended attending CD groups offered with the Schizophrenia Program. However, less than 10% have followed those recommendations and attended the CD group. Based on what is known about challenges surrounding engagement of CD clients in recommended treatments coupled with guidelines for evidence-based treatment with this population (Ledgerwood et al., 2008; Tsuang et al., 2006; Roncero et al., 2011), the purpose of the current study is to explore the ability of MET to increase engagement in CD interventions for clients diagnosed with psychotic and substance use disorders.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Psychosis, Substance Use
Keywords
Psychosis, Substance Use, Motivational Enhancement Therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
8 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Brief Motivational Enhancement Therapy
Arm Type
Experimental
Arm Title
treatment as usual
Arm Type
Other
Intervention Type
Behavioral
Intervention Name(s)
Brief Motivational Enhancement Therapy
Intervention Description
The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
Intervention Type
Other
Intervention Name(s)
treatment as usual
Intervention Description
Treatment as usual includes case management as well as psychiatric appointments.
Primary Outcome Measure Information:
Title
CD group attendance
Description
The primary outcome engagement with outpatient CD service as measured by CD group attendance.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Alcohol Use Scale (AUS)/Drug Use Scale (DUS)
Description
The secondary outcome is change in substance use as measured by the AUS and DUS
Time Frame
2 weeks and 3 months
Other Pre-specified Outcome Measures:
Title
Working Alliance Inventory
Description
A measure of alliance between the participant and the clinician conducting the MET sessions.
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Between the ages of 16-65 DSM-IV Diagnoses of a psychotic disorder and a substance use disorder (tobacco, alcohol and/or drug) Fluent English speaker Capable of giving written informed consent Exclusion Criteria: Any medical or neuropsychiatric condition, illness or disorder (e.g. unstable angina, severe dementia) that could compromise attendance to outpatient appointments. Inability to provide informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yarissa Herman, D.Psych
Organizational Affiliation
Centre for Addiction and Mental Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Addiction and Mental Health
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5T 1R8
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Brief Motivational Enhancement Therapy for Concurrent Disorders

We'll reach out to this number within 24 hrs